Vanta Bioscience share news, announcements and annual reports
BSE: 540729Healthcare ServicesSmall Cap
Vanta Bioscience Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 2017
Last close ₹20.39down ₹0.01 (0.05%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹20.40.
30 Oct: open ₹20.39, high ₹20.39, low ₹20.39
52-week range of traded prices to 30 Oct 2026
₹14.71Low, 24 Mar 2026₹29.00High, 6 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15 Cr4,396th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 133.90
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.80
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 750
Vanta Bioscience board meetings
65 filed, newest first. Page 1 of 2.
Sep 2026
5 Sep · Board meeting
May 2026
26 May · Board meeting
Meeting on 30 May 2026: audited results
Jan 2026
30 Jan · Board meeting
Nov 2025
10 Nov · Board meeting
Meeting on 14 Nov 2025: half yearly results
Sep 2025
6 Sep · Board meeting
Jul 2025
29 Jul · Board meeting
Meeting on 1 Aug 2025: audited results
May 2025
29 May · Board meeting
6 May · Board meeting
Meeting on 6 May 2025: preferential issue of shares
Dec 2024
3 Dec · Board meeting
Meeting on 6 Dec 2024: increase in authorised capital
Nov 2024
14 Nov · Board meeting
11 Nov · Board meeting
Meeting on 14 Nov 2024: half yearly results
Sep 2024
Jul 2024
19 Jul · Board meeting
18 Jul · Board meeting
Meeting on 19 Jul 2024: audited results10 Jul · Board meeting
Meeting on 17 Jul 2024: audited results
Nov 2023
14 Nov · Board meeting
8 Nov · Board meeting
Meeting on 14 Nov 2023: half yearly results
Aug 2023
4 Aug · Board meeting
Meeting on 10 Aug 2023: audited results and half yearly results
May 2023
22 May · Board meeting
Meeting on 30 May 2023: half yearly results and audited results
Nov 2022
9 Nov · Board meeting
Meeting on 14 Nov 2022: half yearly results
May 2022
24 May · Board meeting
Meeting on 30 May 2022: audited results
Nov 2021
3 Nov · Board meeting
Meeting on 11 Nov 2021: half yearly results
Jun 2021
17 Jun · Board meeting
Meeting on 28 Jun 2021: preferential issue of shares and audited results
Nov 2020
5 Nov · Board meeting
Meeting on 13 Nov 2020: half yearly results
Jun 2020
30 Jun · Board meeting
19 Jun · Board meeting
Meeting on 30 Jun 2020: audited results
Mar 2020